ClinicalTrials.gg

Program

BT02

A development code.

Its studies are mostly in Hematologic Neoplasms · Carcinoma, Non-Small-Cell Lung · Melanoma, led by Biotroy Therapeutics.

Furthest: phase 2, since Jul 30, 20253 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biotroy Therapeutics33 open or runningphase 2since Jul 30, 2025Jul 16, 2025Mar 2027phase 1 · NCT07110363

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2025First studies: 2 phase 1 studiesFirst studyNCT07107178, NCT07110363
  2. Jul 30, 2025Phase 2 study in RecurrenceNCT07107204 · 116 planned

Ahead

  1. Mar 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07110363
  2. May 2027Primary completion: phase 1 study in Advanced MelanomaNCT07107178
  3. Jan 2028Primary completion: phase 2 study in RecurrenceNCT07107204

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07107204Recurrence2Not yet recruitingJan 2028116
NCT07110363Carcinoma, Non-Small-Cell Lung1Not yet recruitingMar 202758
NCT07107178Advanced Melanoma1Not yet recruitingMay 202758

How it is read

Names in the registry

  • “BT02”, 3 entries

Codes read as this program: BT02.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.